Home › Compare › GRPTY vs ABBV
GRPTY yields 3.14% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, GRPTY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GRPTY + ABBV for your $10,000?
Getlink SE engages in the design, finance, construction, and operation of fixed link infrastructure and transport system. The company operates through three segments: Eurotunnel, Europorte, and ElecLink. The Eurotunnel segment operates three tunnels of a length of approximately 50 kilometres each under the English Channel, as well as two terminals at Folkestone in the United Kingdom and the Coquelles in France. It also provides passenger shuttle services for the transport of trucks, cars, motor homes, caravans, coaches, and motorcycles. In addition, this segment manages high-speed passenger trains and rail freights, as well as fixed equipment and related installations. The Europorte segment offers a range of integrated rail freight services, including national and international haulage, local services for secondary lines, individual junction management, infrastructure maintenance, and wagon loading and unloading services. The ElecLink segment engages in the construction and operation of a 1 gigawatt electricity interconnector between the United Kingdom and France. Getlink SE also engages in third-party retail, telecommunication cable, training activity, and property businesses, as well as the sale of travel insurance products. The company was formerly known as Groupe Eurotunnel S.E. and changed its name to Getlink SE in April 2018. Getlink SE was founded in 1986 and is headquartered in Paris, France.
Full GRPTY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.